Section Review—Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Trials and Tribulations in the Development of Antigen-Specific Therapies for Rheumatoid Arthritis

References

• ASTORGA GP, WILLIAMS RC, Jr.: Altered reactivity in mixed lymphocyte culture of lymphocytes from pa- tients with RA. Arthritis Rheum. (1969) 12:547–550.
   Google Scholar
• WITEBSICY E, ROSE NR, TERP1AN K, PAINE JR, EGAN RW: Chronic thyroiditis and autoimmunization. J. Amer. Med. Assoc. (1957) 164:14394447. The first description of an autoimmune reaction.
   Google Scholar
• STASNY P, OLSEN N, PINCUS T, KAHN MA, BALL EJ: DR4 and DR1 define different subsets of patients with RA. Immunobtology of HLA (Volume II). Proc. 10th Histocom-pat. Workshop, Berlin. Dupon B (Ed.). Springer Verlag, Berlin (1989):418–419.
   Google Scholar
• GIBOSFSKY A, WINCHESTER RJ, PATARROYO M, ET AL.:Disease-associations of the la-like human alloantigens: contrasting patterns in RA and SLE. J. Exp. Med. (1978) 148: 1728 732.
   Google Scholar
• LEE SH, GREGERSON PK, SHEN HH, NUNEZ-ROLDAN A, SILVER J, WINCHESTER RJ: Strong association of RA with the presence of a polymorphic la epitope defined by a monoclonal antibody: comparison with the allodeter-minant DR4. Rheumato1 Int. (1984) 4\(Suppl. 1):17–23.
   Google Scholar
• DUQUESNOY RJ, MARRARI M, HACKBARTH S, ZEEVI A: Serological and cellular definition of a new HLA-DR-as-sociated determinant, MCI, and its association with RA. Human Immunol. (1984) 10:165–176.
   PubMed Web of Science ®Google Scholar
• GREGERSON PK, SHEN M, SONG QL, MERRYMAN P, DE-GAR S, SEKI T, MACCARI J, GOLDBERG D, MURPHY H, SCHWENZER J: Molecular diversity of HLA-DR4 haplo-types. Proc. Natl. Acad. Sci. (1986) 83:2642–2646.
   PubMed Web of Science ®Google Scholar
• GREGERSON PK, SLIVER J, WINCHESTER RJ: The shared epitope hypothesis - An approach to understanding the molecular genetics of RA susceptibility. Arthritis Rheum. (1987) 30:1205–1213.
   PubMed Web of Science ®Google Scholar
• MERRYMAN PF, CRAPPER RM, LEE S, GREGERSEN PK,WINCHESTER RJ: Class II MHC gene sequences in RA: The third diversity regions of both DRPIL genes in two DR1, DRw10-positive individuals specify the same inferred amino add sequence as the DRI31 and DRI32 genes of a DR4Dw14 haplotype. Arthritis Rheum. (1989) 32:251–258.
   PubMed Web of Science ®Google Scholar
• WORDSWORTH BP, LANCHBURY JS, SAKKAS LL, WELSHKI, PANAYI GS, BELL JI: HLA-DR4 subtype frequencies in RA indicate that DRB1 is the major susceptibility locus within the HIA class II region. Proc. Natl. Acad. Sci. (1989) 86,10049–10053.
   PubMed Web of Science ®Google Scholar
• NEPOM GT, HANSEN JA, NEPOM BS: The molecular basisfor HLA class II associations with RA. J. Clin. Immunol. (1987) 7:1–7.
   PubMed Web of Science ®Google Scholar
• MATSUYAMA T, WINCHESTER RJ, LEE S, SHOOKSTER L,NUNEZ-ROLDAN A: Identification of the DRw10 DRB1 chain allele as encoding a polymorphic class ll MHC epitope otherwise restricted to DRB2 molecules of the DRw53 type. J. Immunol. (1988) 140:537–543.
   PubMed Web of Science ®Google Scholar
• WEYAND CM, GORONZY JJ: Disease-associated HLA de-terminants in patients with seropositive RA. Functional role in antigen-specific and allogeneic T-cell recogni-tion. J. Clin. Invest. (1990) 85:1051–1057.
   Google Scholar
• WEYAND CM, HIJKOCK KC, GORONZY JJ: Nonrandomselection of T-cell specificities in anti-H1A-DR re-sponses. Sequence motifs of the responder HLA-DR allele influence T-cell recruitment. J. Immunol. (1991) 147:70–78.
   Google Scholar
• WEYAND CM, GORONZY JJ: Functional domains on •HLA-DR molecules: Implications for the linkage ofHLA-DR genes to different autoimmune diseases. Clin. Immunol. Immunopath. (1994) 70:91-98. Concise but excellent review of role of HLA and TCR in RA.
   Google Scholar
• WEYAND CM, GORONZY JJ: Soluble HLA-DR molecules in patients with HLA class ll versus class I associated disorders. Auto immunity (1991) 8:281–287.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RH: T-cell allergy. Scientific American (August, 1993):62–71.
   Google Scholar
• • The original description of anergy for non-experts.
   Google Scholar
• WINKELHAKE JL: A dynamic continuum model for mo-lecular regulation of the humoral immune response. J. Theor. Biol. (1976) 60:37–49.
   PubMed Web of Science ®Google Scholar
• JANEWAY CA, Borromur K: Signal and signs for lym.,phoeyte responses. Cell (1994) 76:375-385, Best recent review of the two-signal model of lymphocyte activation.
   Google Scholar
• LANZAVECHH1A A, REID PA, WATTS C: Irreversible asso-ciation of peptide with class Ii MEW molecules in living cells. Nature (1992) 357:249–252.
   PubMed Web of Science ®Google Scholar
• HUGHES A, NEI M: Nucleotide substitution at major histocompatibility complex class II loci: Evidence for overdominant selection. Proc. Natl. Acad. Sci. (1989) 86:958–962.
   PubMed Web of Science ®Google Scholar
• NELSON CA, PETZOLD SJ, UNANUE E: Peptides determinethe lifespan of MHC class ll molecules in the APC. Nature (1994) 371:25–2.
   PubMedGoogle Scholar
• CRESSWELL P: Assembly, transport, and function of MHC class U molecules. Ann. Rev. Immunol. (1994) 12:259. Detailed summary of current knowledge.
   Google Scholar
• RISAU WB, ENGELHARDT B, WEICERLE H: Immune func-tion of the blood brain barrier: incomplete presenta-tion of protein (auto-) antigens by rat microvascular endothelium in vitro. J. Cell. Biol. (1990) 110:1757–1766.
   PubMed Web of Science ®Google Scholar
• WEBER L: Human astrocytes are only partially compe-tent antigen presenting cells (possible implications for lesion development in multiple sclerosis). Brain (1994) 117:59–69.
   PubMed Web of Science ®Google Scholar
• ALBANIS, TUCICWELL J, ESPARZA L, CARSON DA, ROLTDIERJ: The susceptibility sequence to RA is a cross-reactive B-cell epitope shared by E. colt, heat shock protein and the HLA DRB1•0401 molecule. J. Clin. Invest. (1992) 89:327–337.
   Google Scholar
• ROUDIER J, RHODES GH, PE1ERSEN J, VAUGHAN JH,CARSON DA: The EB'V glycoprotein gp110, a molecular link between HLA-DR4, IILA-DR1 and RA. Scand. J. Immunol. (1988) 17:367–374.
   Google Scholar
• ROUDIER J, PETERSEN J, RHODES G, LUKA J, CARSON DA: Susceptibility to RA maps to a T-cell epitope shared by the HLA-Dw4 DRB1 chain and the EBV glycoprotein gp110. Proc. Natl. Acad. Sci. (1989) s6:5104–5108.
   Google Scholar
• WEYAND C, XIE C, GORONZY J: Homozygosity for the HLA-DRB1 alleles selects for extrartkular manifesta-tions in RA. J. Clin. Invest. (1992) 89:2033–2039.
   PubMed Web of Science ®Google Scholar
• MERRYMAN PF, CRAPPER RM, LEE S, GREGERSEN PK, WINCHESTER RJ: Class HMHC gene sequences in RA: The third diversity regions of both DRIS1 genes in two DR1, DRw10-positive individuals specify the same inferred amino acid sequence as the DRI31 and DR112 genes of a DR4Dw14 haplotype. Arthritis Rheum. (1989) 32:251–258.
   PubMed Web of Science ®Google Scholar
• MOREL PA, HORN GT, BLTDD R, EHRLICH HA, FATHMAN CG: Shared molecular markers of genetic predisposi-tion to seropositive RA. Hum. Immunol. (1990) 27:90–99.
   PubMed Web of Science ®Google Scholar
• NELSON JL, DUGOWSON CE, KOEPSELL TD, VOIGT LF, BRANCHALTD AM, BARRINGTON RA, WENER MH, HANSEN JA: RF, HLA-DR4 and allelic variants of DRB1 in women with recent-onset RA. Arthritis Rheum. (1994) 37:673–680.
   PubMed Web of Science ®Google Scholar
• NEPOM GT, NEPOM BS: Prediction of susceptibility toRA by HLA genotyping. Rheum. Dis. Gun. North Amer. (1992) 18:785–792.
   PubMed Web of Science ®Google Scholar
• NELSON JL, HUGHES KA, SMITH AG: Maternal-fetal dis-parity in HLA class U alloantigens and the pregnancy-induced amelioration of RA. New Engl. J. Med. (1993) 329:466–471.
   PubMed Web of Science ®Google Scholar
• SCHAEFER EB, SETTE A, JOHNSON DL, BEKOFF MC, SMITH JA, GREY HM, BUDS S: Relative contribution of determi-nant selection and holes in the T-cell repertoire to T-cell responses. Proc. Natl. Acad. Sci. (1989) 86:4649–4653.
   PubMed Web of Science ®Google Scholar
• WEYAND CM, OPPTTZ U, HICOK K, GORONZY JJ: Selec-tion of T-cell receptor VB elements by HLA-DR determi-nants predisposing to RA. Arthritis Rheum. (1992) 5:990–1008.
   Google Scholar
• KAVALER J, DAVIS M, CHIEN Y: Localization of a T-cellreceptor diversity-region element. Nature (1984) 310:421.
   PubMed Web of Science ®Google Scholar
• SIU G, KRONENBERG M, STRAUSS E, HAARS R, MAK TW,HOOD L: The 1313 gene segments of the murine T-cell antigen: Structure, rearrangement, and expression. Na-ture (1984) 311:344.
   PubMed Web of Science ®Google Scholar
• SAITO H, KRANZ DM, TAKAGAKI Y, HAYDAY AC, EISENHN, TONEGAWA S: A third rearranged and expressed gene in a clone of cytotoxic T-Iymphocytes. Nature (1984) 312:36–40.
   PubMed Web of Science ®Google Scholar
• BRENNER MB, STROMINGER JL, KRANGEL MS: The y/8 T-cell receptor. Adv. Immunol. (1988) 43:133.
   PubMed Web of Science ®Google Scholar
• BRENNER MB, STROMINGER JL, KRANGEL MS: Identifica-tion of a putative second T-cell receptor. Nature (1988) 322:145.
   Google Scholar
• SAITO H, KRANZ DM, TAKAGAKI Y, HAYDAY AC, EISEN HN, TONEGAWA S: Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA se-quences. Nature (1984) 309:757–762.
   PubMed Web of Science ®Google Scholar
• WEISS A, STOBO JD: Requirement for the coexpression of T3 and the T-cell antigen receptor on a malignant human T-cell line. J. E. Med. (1984) 160:128.
   Google Scholar
• JANEWAY CA, Jr.: The T-cell receptor as a multicompo-nent signalling machine: CD4/CD8 coreceptors and CD45 in T-cell activation. Ann. Rev. Immunol. (1992) 10:83.
   Google Scholar
• DAVIS MM, BJORKMAN PJ: T-cell antigen receptor genes and T-cell recognition. Nature (1988) 334:395.
   PubMed Web of Science ®Google Scholar
• CHOTHIA C, BOSWELL DR, LESK AM: The outline struc- ture of the T-cell alpha beta receptor. EMBO J. (1988) 7:3745.
   Google Scholar
• CLAVERLE JM, PROCHNICKA CA, BOUGUELERT L: Impli-cations of a Fab-like structure for the T-cell receptor. Immunol. Today (1989) 10:10.
   PubMedGoogle Scholar
• MATSUI K, BONIFACE JJ, REAY PA, SCHILD H, FAZEKAS DE ST GROTH B, DAVIS MM: Low affinity interaction of peptide-MHC complexes with T-cell receptors. Science (1991) 254:1788–1791.
   PubMed Web of Science ®Google Scholar
• WEBER S, TRAUNECKER A, OLIVERI F, GERHARD W, KARJALAINEN K: Specific low-affinity recognition of major histocompatibility complex plus peptide by sol- uble T-cell receptor. Nature (1992) 356:793-796. Important discovery which relates to overall mechanisms of action.
   Google Scholar
• WILLIAMS AF, BEYERS AD: T-cell receptors: At grips with Interactions. Nature (1992) 356:746.
   PubMed Web of Science ®Google Scholar
• VON BOEHMER H: The developmental biology of T-lym-phocytes. Ann. Rev. Immunol. (1988) 6:309–322.
   PubMed Web of Science ®Google Scholar
• DAVIS MM: T-cell receptor gene diversity and selection.
   Google Scholar
• Ann. Rev. Biochem. (1990) 59:475-496. Good concise review of this complex area.
   Google Scholar
• GORONZY JJ, BARTZ-BAZZANELLA P, HU W, JENDRO MC, WALSER-KUNTZ DR, WEYAND CM: Dominant clonotypes In the repertoire of peripheral CD4' T-cells in RA. J. (lin. Invest. (1994) 94:2068–2076.
   PubMed Web of Science ®Google Scholar
• ZAGON G, TUMANG J, LI Y, POSTNETT DN, FRIEDMAN SM, CROW MK: Synovial T-cell repertoire and functional analysis in patients with RA. Arthritis Rheum. (1993) 36:S197.
   Web of Science ®Google Scholar
• CHOI Y, LAFFERTY JA, CLEMENTS JR, TODD JK, GELFANDEW, KAPPLER J, MARRACK P, KOTZIN B: Selective expan-sion of T-cells expressing VB2 in toxic shock syndrome. J. Exp. Med. (1990) 172:981–984.
   PubMed Web of Science ®Google Scholar
• RELLAHAM BL, JONES LA, KRUISBEEK AM, FRY AM, MATISLA: In vivo induction of anergy in peripheral VB8+ T-cells by staphylococcal enterotoxin B. J. Exp. Med. (1990) 172:1091–1100.
   PubMed Web of Science ®Google Scholar
• JENKINS MK, JOHNSON JG: Molecules involved in T-cell costimulation. Gum. Opin. Immunol. (1993) 5:361–367.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, LEDBETTER JA: The role of the CD28 receptor during T-cell responses to antigen. Ann. Rev. Immunol.(1993) 11:191-212. Excellent review in this rapidly-progressing arena.
   Google Scholar
• HEMLER ME, ELICES MJ, PARKER C, TAICADA Y: Structure of the integrin VIA-4 and its cell-cell and cell-matrix adhesion functions. Immunol. Rev. (1990) 114:45–65.
   PubMed Web of Science ®Google Scholar
• MALIK AB: Endothelial cell interactions and integrins.New Horizons (1993) 1:37–51.
   PubMedGoogle Scholar
• WUTHRICH RP, JEVNIKAR AM, TAKEI F, GLIMCHER LH, KELLEY VE: ICAM-1 expression is upregulated in autoim-mune murine lupus nephritis. Am. J. Pathol. (1990) 136:441-450. Concise description for the nomenclature-naive.
   Google Scholar
• ZENG RQ, ABNEY ER, GRUBECK-LOEBENSTEIN B, DAVAN C, MAINI RN, FELDMANN M: Expression of ICAM-1 and LFA-3 on human thryoid epithelial cells in Graves' and Hashimoto's diseases. J. Autoimmun. (1990) 3:727–736.
   PubMedGoogle Scholar
• BOUSSIOTIS VA, FREEMAN GJ, GRAY G, GRIBBEN J, NADLER LM: B7 but not ICAM-1 costimulation prevents the induction of human alloantigen-specific tolerance. J. Exp. Med. (1993) 178:1753–1763.
   PubMed Web of Science ®Google Scholar
• TAN P, ANASEITI C, HANSEN JA, MELROSE J, BRUNVAND M, BRADSHAW J, LEDBEII ER JA, LINSLEY PS: Inductionof alloantigen-specific hyporesponsiveness in human T-lymphocytes by blocking interaction of CD28 with its natural ligand B7. J. Exp. Med. (1993) 177:165–173.
   PubMed Web of Science ®Google Scholar
• GIMMI CD, FREEMAN GJ, GRIBBEN JG, GRAY G, NADLER LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. (1993) 90:6586–6590.
   PubMed Web of Science ®Google Scholar
• GRIBBEN JG, FREEMAN GJ, BOUISSIOTIS VA, RENNERT P,JELLIS CL, GREENFIELD E, BARBER M, RESTIVO VA Jr., XEAOYAN K, GRAY GS, NADLER LM: CT1A4 me-Antes antigen-specific apoptosis of human T-cells. Proc. Natl. Acad. Sci. USA (1995) 92:811–815.
   Google Scholar
• WEYAND CM, MCCARTHY TG, GORONZY JJ: J. Clin. Invest. (1995). In press.
   Google Scholar
• MORGAN K, CLAGUE RB, COLLINS I, AYAD S, PHINN SD, HOLT PJL: A longitudinal study of anticollagen antibod-ies in patients with rheumatoid arthritis. Arthritis Rheum. (1989) 32:1087–1092.
   PubMedGoogle Scholar
• SOLLNGER AM, BHATNAGAR RS, STOBO JD: Cellular, molecular and genetic characteristics of T-cell reactivity to collagen in man. Proc. Natl. Acad. Sci. (1981) 78:3877–3881.
   PubMed Web of Science ®Google Scholar
• SOLINGER AM, STOBO JD: Immune response gene con-trol of collagen reactivity in man: collagen unrespon-siveness in HLA DR4 negative nonresponders due to the presence of T-cell dependent suppressive influences. J. Immunol. (1982) 129:1916–1922.
   PubMed Web of Science ®Google Scholar
• STROM H, AL-BALAGHI S, MOLLER E: No demonstrable association between HLA DR4 and in vitro collagen reactivity as determined by the production of leukocyte inhibition factor. Tissue Antigen (1984) 24:174–183.
   PubMed Web of Science ®Google Scholar
• STUART JM, HUFFSTUI ILR EH, TOWNES AS, KANG All:Incidence and specificity of antibodies to types I, II, II, IV, and V collagen in rheumatoid arthritis and other rheumatic diseases as measured by 125I-radioinunu-noassay. Arthritis Rheum. (1983) 26:832–840.
   PubMed Web of Science ®Google Scholar
• ROWLEY M, TAIT B, MACKAY IR, CUNNINGHAM T, PHIL-LIPS B: Collagen antibodies in rheumatoid arthritis: significance of antibodies to denatured collagen and their association with FILA.-DR4. Arthritis Rheum. (1986) 29:174–184.
   Google Scholar
• TARKOWSKI A, KLARESKOG L, CARLSTEN H, HERBERTS P,KOOPMAN WJ: Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheu-matoid arthritis. Arthritis Rheum. (1989) 32:1087–1092.
   PubMed Web of Science ®Google Scholar
• RONNELID J, LYSHOLM J, ENGSTRON-LAURENT A, KLARESKOG L, HEYMAN B: Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Arthritis Rheum. (1994) 37:1023–1029.
   PubMed Web of Science ®Google Scholar
• ICAVANAUGH AF, DAVIS LS, NICHOLS LA, NORRIS SH, ROTH1EIN R, SCHARSCHID LA, LIPSKY PE: Treatment of refractory rheumatoid arthritis with a monoclonal an-tibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37:992–999.
   PubMed Web of Science ®Google Scholar
• DAVIS LS, LIPSKY PE: Tolerance induction of human •CD4 cells: Markedly-enhanced sensitivity of memoryversus naive T cells to peripheral allergy. Cellular Im-munol. (1993) 146:351-361. First discovery in humans of an important aspect of autoimmunity - the role of peripheral tolerance.
   Google Scholar
• WALDMANN H, COBBOLD S: The use of monoclonal antibodies to achieve immunological tolerance. Immu-nol. Today (1993) 14:247–251.
   PubMedGoogle Scholar
• LINSEY PS, LEDBEII ER JA: The role of the CD28 receptor during T-cell responses to antigen. Ann Rev. Immunol. (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBEIIER JA: MA-4 is a second receptor for theB-cell activation antigen B7. J. Exp. Med. (1991) 174:561–569.
   PubMed Web of Science ®Google Scholar
• LEUNG HT, LINSLEY PS: The CO28 costknulatory path-way. Therapeut. Immunol. (1994) 1:217–228.
   PubMedGoogle Scholar
• LEDBE11ER JA, WALLACE PM, JOHNSON J, GIBSON MG, GREENE JL, SINGH C, TEPPER MA: Inununosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule. Science (1994 257:792–795,
   Google Scholar
• MORELAND LW, PRATT PW, BUCY RP, JACKSON BS, FELD-MAN JW, KOOPMAN WJ: Treatment of refractory RA with a chimeric anti-CD4 monoclonal antibody. Long-term follow-up of CD4' T-cell counts. Arthritis Rheum. (1994) 37:834–838.
   Google Scholar
• NAG B, MUKKU PV, ARIMILLY S, PHAN D, DESHPANDE SV,WINKELHAKE JL: Antigenic peptide binding to MHC class II molecules at increased peptide concentrations. Mot. Immunol. (1994) 31:1161–1168.
   Google Scholar
• HAMMER J, BELUNIS C, BOLIN D, PAPADOPOULOS J, WALSKY R, HIGELIN J, DONHO W, SINIGAGLIA F, NAGY • Z: High-affinity binding of short peptides to major laistocompatibility complex class II molecules by an-chor combinations. Proc. Natl. Acad. Sci. (1994) 91:4456-4460. Type of work required to identify the autoantigenic peptide(s) in RA.
   Google Scholar
• ADELMAN NC, WATLING DL, MCDEVITT HO: Treatment of (NZB X NZW) Fl disease with anti-Lk monoclonal antibodies. J. Exp. Med. (1983) 158:1350–1355.
   PubMed Web of Science ®Google Scholar
• SRIRAM S, STEINMAN LS: Anti-IA antivody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J.ExpMed. (1983) 158:1362–67.
   Web of Science ®Google Scholar
• WALDOR MK, SRIRAM S, MCDEBITT HO, STEINMAN L: Invivo therapy with monoclonal antibody to IA antigen suppresses the response to acetylcholine receptor. Frye. Natl. Acad. Sci. USA (1983) 80:2713–2716.
   PubMed Web of Science ®Google Scholar
• WOOLLY PH, LUTHRA HS, LAFUSE WP, HUSE A, STUARTJM, DAVID CS: Type ll collagen-induced arthritis in mice. 111. Suppression of arthritis by using monoclonal and polyclonal anti-Lk antisera. J. Immunol. (1984) 134:2366–2374.
   Google Scholar
• VLADUTIO AO, STEINMAN L: Inhibition of experimentalautoinunune thyroiditis in mice. Cellular Immunol. (1987) 109:169–180.
   PubMed Web of Science ®Google Scholar
• TOPHAM DJ, NAG B, ARIMILLI S, SRIRAM S: A syntheticpeptide from the third hypervariable region of MHC class II l chain as a vaccine for treatment of EAR. Proc. Natl. Acad. Sci. USA (1994) 91:8005–8009.
   PubMed Web of Science ®Google Scholar
• AGRAWAL B, MANICK JASUNARI M, FRAGA E, SINGH B:T-cells that recognize peptide sequences of self MHC class II molecules exist in syngeneic mice. J. lmmunol. (1991) 147:383–387.
   PubMed Web of Science ®Google Scholar
• BENICHOU G, TAKIZAWA PA, HO PT, KILLION CC, OLSON CA, MCMILLAN M, SERCARZ EE: Lmmunogenicity and tolerogenicity of self MHC peptides. J. Exp. Med. (1990) 172:1341-1354. Describes a new concept of self-recognition control.
   Google Scholar
• SALVAT S, AUGER I, ROCHELLE L, BEGOVICH A, GEBUR-HER L, SEI-lt. A, ROUDLER J: Tolerance to a sell-peptide from the third hypervariable region of LILA DRB1•0401 In RA patients and normal subjects. J. Immunol. (1994) 153:5321–5329.
   Google Scholar
• SCHNECK J, MALOY WL, COLIGAN JE, MARGULIS DH: Inhibition of an allospecific T-cell hybridoma by sol-uble class I proteins and peptides: estimation of the affinity of a T-cell receptor for MHC. Cell (1989) 56:47–55.
   PubMed Web of Science ®Google Scholar
• LI H-F, FAN T-D, PAN C-B, GEFTER ML, LAI M-Z: Modula-tion of restricted class 11 T-cell responses by peptides derived from self class II molecules. J. Immunol. (1992) 22:2527–2531.
   Web of Science ®Google Scholar
• FIRESTEIN GS, ZVAIFLER NJ: How important are T-cells in chronic rheumatoid synovitis? Arthritis Rheum. (1990) 33:767-773. A valid counterpoint to the role of T-cells in RA.
   Google Scholar
• CLAUBERGER C, SHU-CHEN L, DEKRUYFF R: Peptides corresponding to the CD8 and CD4 binding domains of HIA molecules block T-lymphocyte immune responses in vitro. J. Immunol. (1994) 153:946–951.
   PubMed Web of Science ®Google Scholar
• OFFNER H, HASHIM GA, VANDERBARK AA: T-cell recep-tor peptide therapy triggers autoregulation of experi-mental encephalomyelitis. Science (1991) 251:430–432.
   PubMed Web of Science ®Google Scholar
• GORONZY JJ, BAZZANELLA-BARTZ P, HU W, JENDRO MC, WALSER-KUNTZ R, WEYAND CM: Dominant clonotypes In the repertoire of peripheral CD4' T-cells in rheuma-toid arthritis. J. Clin. Invest. (1994) 94:2068–2076.
   PubMed Web of Science ®Google Scholar
• MADDEN DR, GORGA JC, STROMINGER JL, WILEY DC: The three-dimensional structure of HLA-B27 at 2,1 a resolu- lion suggests a general mechanism for tight peptide binding to MHC. Cell (1992) 70:1035–1048.
   PubMed Web of Science ®Google Scholar
• WELLS HG: Studies on the chemistry of anaphylaxis. M.
   Google Scholar
• •Experiments with isolated proteins, especially those of the hen's egg. J. Infect. Ms. (1908) 5:449-483. One of the first descriptions of oral tolerance in the scientific literature.
   Google Scholar
• TRENTHAM DE, DYNESIUM-TRENTHAM A, ORAV EJ, COM-BITCH' D, LORENZO C, SEWELL KL, HAFLER DA, WEINER HL: Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 261:1727–1730.
   PubMed Web of Science ®Google Scholar
• STEVENS FA: Status of poison ivy extracts. Report of the Council on Pharmacy & Chemistry. J. Amer. Med. Assoc. (1945) 7:912-921. A good description of the types of results obtained (even today) in clinical studies of oral tolerance.
   Google Scholar
• AL-SABBUGH A, MILLER A, SANTOS L, WEINER HL: Anti-gen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur. J. Immunol. (1994) 24:2104–2109.
   PubMed Web of Science ®Google Scholar
• SHARMA SD, NAG B, SU X-M, GREEN K, SPACK E, CLARK B, SRIRAM S: Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc. Natl. Acad. Sci. (1991) 88:11465-11469. One of the first indications of the need for two signals in lymphocyte activation - one signal alone inducing anergy.
   Google Scholar
• MUKKU P, PASSMORE D, PHAN D, NAG B: pH dependent binding of high and low affinity myelin basic protein peptides to purified IILA-DR2. Mol. Immunol. (1995). In press.
   Google Scholar
• NICOILP M, NAG B, SHARMA SD, WILLCOX N, VINCENT A, FERGUSON DJ, NEWSOME-DAVIS J: Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4 lymphocytes by soluble MHC class II-peptide complexes. J. Clin. Invest. (1994) 91:6/6-628. Initial studies differentiating anergy from clonal deletion (apoptosis).
   Google Scholar